{
    "address1": "777 Old Saw Mill River Road",
    "city": "Tarrytown",
    "state": "NY",
    "zip": "10591-6707",
    "country": "United States",
    "phone": "914 847 7000",
    "website": "https://www.regeneron.com",
    "industry": "Biotechnology",
    "industryKey": "biotechnology",
    "industryDisp": "Biotechnology",
    "sector": "Healthcare",
    "sectorKey": "healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",
    "fullTimeEmployees": 15222,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Dr. Leonard S. Schleifer M.D., Ph.D.",
            "age": 71,
            "title": "Co-Founder, President, CEO & Co-Chairman",
            "yearBorn": 1953,
            "fiscalYear": 2024,
            "totalPay": 6823034,
            "exercisedValue": 117275128,
            "unexercisedValue": 192379808
        },
        {
            "maxAge": 1,
            "name": "Dr. George D. Yancopoulos M.D., Ph.D.",
            "age": 64,
            "title": "Co-Founder, President, Chief Scientific Officer & Co-Chairman",
            "yearBorn": 1960,
            "fiscalYear": 2024,
            "totalPay": 6796783,
            "exercisedValue": 95717904,
            "unexercisedValue": 188321072
        },
        {
            "maxAge": 1,
            "name": "Mr. Christopher R. Fenimore CPA",
            "age": 53,
            "title": "Executive VP of Finance & CFO",
            "yearBorn": 1971,
            "fiscalYear": 2024,
            "totalPay": 1269250,
            "exercisedValue": 9054700,
            "unexercisedValue": 16618295
        },
        {
            "maxAge": 1,
            "name": "Dr. Andrew J. Murphy Ph.D.",
            "age": 66,
            "title": "Executive VP of Research & Co-Chief Scientific Officer",
            "yearBorn": 1958,
            "fiscalYear": 2024,
            "totalPay": 1613560,
            "exercisedValue": 26279800,
            "unexercisedValue": 56244512
        },
        {
            "maxAge": 1,
            "name": "Mr. Daniel P. Van Plew",
            "age": 51,
            "title": "Executive VP and GM of Industrial Operations & Product Supply",
            "yearBorn": 1973,
            "fiscalYear": 2024,
            "totalPay": 1905481,
            "exercisedValue": 20283170,
            "unexercisedValue": 9502018
        },
        {
            "maxAge": 1,
            "name": "Mr. Rajesh  Ahuja",
            "title": "Senior Vice President of Quality Assurance & Operations",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Bob  McCowan",
            "title": "Senior VP of IT & Chief Information Officer",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Ryan  Crowe",
            "title": "Senior Vice President of Investor Relations & Strategic Analysis",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Joseph J. LaRosa J.D.",
            "age": 65,
            "title": "Executive VP, General Counsel & Secretary",
            "yearBorn": 1959,
            "fiscalYear": 2024,
            "totalPay": 1748110,
            "exercisedValue": 23227300,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Melissa  Lozner",
            "title": "Senior VP & Chief Compliance Officer",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 8,
    "boardRisk": 10,
    "compensationRisk": 9,
    "shareHolderRightsRisk": 10,
    "overallRisk": 10,
    "governanceEpochDate": 1761955200,
    "compensationAsOfEpochDate": 1735603200,
    "irWebsite": "http://newsroom.regeneron.com/",
    "executiveTeam": [],
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 654.04,
    "open": 649.45,
    "dayLow": 645.0,
    "dayHigh": 659.76,
    "regularMarketPreviousClose": 654.04,
    "regularMarketOpen": 649.45,
    "regularMarketDayLow": 645.0,
    "regularMarketDayHigh": 659.76,
    "dividendRate": 3.52,
    "dividendYield": 0.54,
    "exDividendDate": 1763596800,
    "payoutRatio": 0.0633,
    "beta": 0.307,
    "trailingPE": 15.623201,
    "forwardPE": 14.3853445,
    "volume": 798001,
    "regularMarketVolume": 798001,
    "averageVolume": 1060101,
    "averageVolume10days": 1067910,
    "averageDailyVolume10Day": 1067910,
    "bid": 650.39,
    "ask": 652.54,
    "bidSize": 1,
    "askSize": 1,
    "marketCap": 68503830528,
    "fiftyTwoWeekLow": 476.49,
    "fiftyTwoWeekHigh": 852.01,
    "allTimeHigh": 1211.2,
    "allTimeLow": 3.0,
    "priceToSalesTrailing12Months": 4.8080287,
    "fiftyDayAverage": 581.9792,
    "twoHundredDayAverage": 596.2645,
    "trailingAnnualDividendRate": 2.64,
    "trailingAnnualDividendYield": 0.0040364508,
    "currency": "USD",
    "tradeable": false,
    "enterpriseValue": 61136232448,
    "profitMargins": 0.32131,
    "floatShares": 98565253,
    "sharesOutstanding": 103282318,
    "sharesShort": 2927169,
    "sharesShortPriorMonth": 2985318,
    "sharesShortPreviousMonthDate": 1757894400,
    "dateShortInterest": 1760486400,
    "sharesPercentSharesOut": 0.0276,
    "heldPercentInsiders": 0.01953,
    "heldPercentInstitutions": 0.91205,
    "shortRatio": 2.48,
    "shortPercentOfFloat": 0.0292,
    "impliedSharesOutstanding": 105099464,
    "bookValue": 301.146,
    "priceToBook": 2.1643987,
    "lastFiscalYearEnd": 1735603200,
    "nextFiscalYearEnd": 1767139200,
    "mostRecentQuarter": 1759190400,
    "earningsQuarterlyGrowth": 0.089,
    "netIncomeToCommon": 4577999872,
    "trailingEps": 41.72,
    "forwardEps": 45.31,
    "enterpriseToRevenue": 4.291,
    "enterpriseToEbitda": 14.061,
    "52WeekChange": -0.21359974,
    "SandP52WeekChange": 0.19736934,
    "lastDividendValue": 0.88,
    "lastDividendDate": 1755475200,
    "quoteType": "EQUITY",
    "currentPrice": 651.8,
    "targetHighPrice": 910.0,
    "targetLowPrice": 595.0,
    "targetMeanPrice": 750.5736,
    "targetMedianPrice": 750.0,
    "recommendationMean": 1.68,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 25,
    "totalCash": 8443599872,
    "totalCashPerShare": 82.297,
    "ebitda": 4348000256,
    "totalDebt": 2705499904,
    "quickRatio": 3.193,
    "currentRatio": 4.063,
    "totalRevenue": 14247799808,
    "debtToEquity": 8.739,
    "revenuePerShare": 134.763,
    "returnOnAssets": 0.06157,
    "returnOnEquity": 0.15188,
    "grossProfits": 6530100224,
    "freeCashflow": 3511000064,
    "operatingCashflow": 5071000064,
    "earningsGrowth": 0.18,
    "revenueGrowth": 0.009,
    "grossMargins": 0.45832002,
    "ebitdaMargins": 0.30517,
    "operatingMargins": 0.29563,
    "financialCurrency": "USD",
    "symbol": "REGN",
    "language": "en-US",
    "region": "US",
    "typeDisp": "Equity",
    "quoteSourceName": "Nasdaq Real Time Price",
    "triggerable": true,
    "customPriceAlertConfidence": "HIGH",
    "longName": "Regeneron Pharmaceuticals, Inc.",
    "hasPrePostMarketData": true,
    "firstTradeDateMilliseconds": 670602600000,
    "postMarketChangePercent": -0.27615646,
    "postMarketPrice": 650.0,
    "postMarketChange": -1.7999878,
    "regularMarketChange": -2.2399902,
    "regularMarketDayRange": "645.0 - 659.76",
    "fullExchangeName": "NasdaqGS",
    "averageDailyVolume3Month": 1060101,
    "fiftyTwoWeekLowChange": 175.31,
    "fiftyTwoWeekLowChangePercent": 0.3679196,
    "fiftyTwoWeekRange": "476.49 - 852.01",
    "fiftyTwoWeekHighChange": -200.21002,
    "fiftyTwoWeekHighChangePercent": -0.23498553,
    "fiftyTwoWeekChangePercent": -21.359974,
    "dividendDate": 1764892800,
    "earningsTimestamp": 1761654600,
    "earningsTimestampStart": 1761654600,
    "earningsTimestampEnd": 1761654600,
    "earningsCallTimestampStart": 1761654600,
    "earningsCallTimestampEnd": 1761654600,
    "isEarningsDateEstimate": false,
    "epsTrailingTwelveMonths": 41.72,
    "epsForward": 45.31,
    "epsCurrentYear": 43.23486,
    "priceEpsCurrentYear": 15.075797,
    "marketState": "CLOSED",
    "shortName": "Regeneron Pharmaceuticals, Inc.",
    "messageBoardId": "finmb_33715",
    "exchangeTimezoneName": "America/New_York",
    "exchangeTimezoneShortName": "EST",
    "gmtOffSetMilliseconds": -18000000,
    "market": "us_market",
    "esgPopulated": false,
    "regularMarketChangePercent": -0.34248522,
    "regularMarketPrice": 651.8,
    "fiftyDayAverageChange": 69.8208,
    "fiftyDayAverageChangePercent": 0.119971305,
    "twoHundredDayAverageChange": 55.53546,
    "twoHundredDayAverageChangePercent": 0.09313896,
    "sourceInterval": 15,
    "exchangeDataDelayedBy": 0,
    "averageAnalystRating": "1.7 - Buy",
    "cryptoTradeable": false,
    "corporateActions": [
        {
            "header": "Dividend",
            "message": "REGN announced a cash dividend of 0.88 with an ex-date of Nov. 20, 2025",
            "meta": {
                "eventType": "DIVIDEND",
                "dateEpochMs": 1763614800000,
                "amount": "0.88"
            }
        }
    ],
    "postMarketTime": 1761955188,
    "regularMarketTime": 1761940800,
    "exchange": "NMS",
    "displayName": "Regeneron Pharmaceuticals",
    "trailingPegRatio": 1.154
}